PPAR-α targeting in kidney fibrosis: is BAY PP1 just another renoprotector?
Interstitial fibrosis plays a major role in the progression of renal diseases. Peroxisome proliferator-activated receptor-α (PPAR-α) ligands are increasingly explored for their potential to reverse or halt tubulointerstitial fibrosis. This Commentary discusses new findings by Boor et al., who show that BAY PP1, a novel PPAR-α agonist, ameliorates renal fibrosis and dysfunction.